H. Knox

Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us.

C. Graham, M. Jen, L. Hess, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer

C. Graham, L. Hess, K. Winfree, 2015, Advances in Therapy.

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

G. Auzinger, C. Charbonneau, C. Graham, 2015, BMC Infectious Diseases.

Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.

B. Barber, C. Graham, G. Hechmati, 2014, European journal of cancer.

P159 Attacks avoided and cost offsets associated with subcutaneous C1-inhibitor (human) long-term prophylaxis of hereditary angioedema

T. Machnig, G. Krishnarajah, D. Supina, 2017 .

Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

M. Fakih, B. Barber, C. Graham, 2015, Journal of medical economics.

A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US

C. Graham, J. Strickler, G. Hechmati, 2018, Journal of medical economics.

Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.

M. Fakih, T. Price, B. Barber, 2016, Clinical therapeutics.

Cost-effectiveness analysis of panitumumab plus mFOLFOX 6 compared with bevacizumab plus mFOLFOX 6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

B. Barber, C. Graham, G. Hechmati, 2014 .

Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.

G. de Pouvourville, B. Barber, C. Graham, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.